Trial reportBlood2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 2 pooled it
22.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
199 citing papers in PubMed, 2 syntheses or guidelines pooled it, 338 citations in OpenAlex.
- Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials.Frontiers in immunology · 2023Pooled it
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.Frontiers in oncology · 2020Pooled it
- Trial
- Trial
- Trial
- BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.Blood · 2021Trial
- Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Trial
- Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).Acta haematologica · 2019Trial
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.Blood · 2018Trial
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Nature communications · 2017Trial
- Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.Molecular therapy. Oncology · 2026Review
- ComplexInternational journal of molecular sciences · 2026Review
- Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.Journal of clinical medicine · 2026Review
- Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.Cancer medicine · 2026Article
- Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding.Current research in structural biology · 2026Article
- Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.Cell genomics · 2026Article
- BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.Biomolecules · 2026Review
- Non-Malignant T Cells as Determinants of Immunotherapeutic Response in Chronic Lymphocytic Leukemia: Towards Personalized Strategies.Oncology research · 2026Review
- Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
139 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 2 countries.
Inhye E AhnMedical Oncology Service, National Cancer Institute, and.
Chingiz UnderbayevHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Adam AlbitarNeoGenomics Laboratories, Irvine, CA; and.
Sarah E M HermanHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Xin TianOffice of Biostatistics Research, National Heart, Lung, and Blood Institute.
Irina MaricDepartment of Laboratory Medicine, Clinical Center, and.
Diane C ArthurLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Laura WakeLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Stefania PittalugaLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Constance M YuanLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Maryalice Stetler-StevensonLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Susan SotoHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Janet ValdezHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Pia NiermanHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Jennifer LotterHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Liqiang XiLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mark RaffeldLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mohammed FarooquiHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Maher AlbitarNeoGenomics Laboratories, Irvine, CA; and.
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
National Institutes of Health · USNational Heart Lung and Blood Institute · USNational Cancer Institute · USNeoGenomics (United States) · USCancer Institute (WIA) · INCenter for Clinical Research (United States) · US
Funding
Molecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8MTumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8MBone Marrow Histopathological Changes in Neoplastic and Non-Neoplastic DiseasesZIACL090027 · CLC · CLINICAL CENTER · PI MARIC, IRINA · 2010 to 2025
$0kAbstract
Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in
Indexed as
Clonal EvolutionDrug Resistance, NeoplasmAdenineAgammaglobulinaemia Tyrosine KinaseAgedCell Transformation, NeoplasticDisease-Free SurvivalDisease ProgressionFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellPhospholipase C gammaPiperidinesProtein-Tyrosine KinasesPyrazolesPyrimidinesAdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibPhospholipase C gammaPiperidinesProtein-Tyrosine KinasesPyrazolesPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.